JPMorgan Starts Neurogene (NGNE) at Overweight

October 8, 2026 3:14 AM

JPMorgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ: NGNE) with a Overweight rating and a price target of $60.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found